BSE Live
Nov 03, 12:30Prev. Close
6746.15
Open Price
6714.25
Bid Price (Qty.)
6796.50 (2)
Offer Price (Qty.)
6802.45 (15)
NSE Live
Nov 03, 12:30Prev. Close
6738.00
Open Price
6738.00
Bid Price (Qty.)
6799.50 (1)
Offer Price (Qty.)
6800.00 (152)
| Cash Flow of Divis Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 2,916.00 | 2,163.00 | 2,368.63 | 3,683.50 | 2,666.04 | |
| Net CashFlow From Operating Activities | 1,653.00 | 1,261.00 | 2,459.73 | 1,911.80 | 1,946.93 | |
| Net Cash Used In Investing Activities | -804.00 | -269.00 | -2,707.62 | -2,194.92 | 75.13 | |
| Net Cash Used From Financing Activities | -799.00 | -799.00 | -797.17 | -532.44 | -34.89 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 50.00 | 193.00 | -1,045.06 | -815.56 | 1,987.17 | |
| Cash And Cash Equivalents Begin of Year | 363.00 | 170.00 | 1,214.76 | 2,030.32 | 43.15 | |
| Cash And Cash Equivalents End Of Year | 413.00 | 363.00 | 169.70 | 1,214.76 | 2,030.32 |
10.09.2025
Reduce Divis Laboratories; target of Rs 5400: Geojit Financial Services
07.08.2025
Accumulate Divis Laboratories; target of Rs 6550: Prabhudas Lilladher
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
23.05.2025
Accumulate Divis Laboratories; target of Rs 7518: Deven Choksey
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
19.05.2025
Divis Labs Consolidated March 2025 Net Sales at Rs 2,585.00 crore, up 12.24% Y-o-Y
19.05.2025
Divis Labs Standalone March 2025 Net Sales at Rs 2,536.00 crore, up 12.26% Y-o-Y
03.02.2025
Divis Labs Consolidated December 2024 Net Sales at Rs 2,319.00 crore, up 25.01% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill